- Home
- STTK vs SXTC Comparison
STTK vs SXTC Comparison
Compare STTK & SXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SXTC
- Stock Information
- Founded
- STTK 2016
- SXTC 2005
- Country
- STTK United States
- SXTC China
- Employees
- STTK N/A
- SXTC N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SXTC Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- SXTC Health Care
- Exchange
- STTK Nasdaq
- SXTC Nasdaq
- Market Cap
- STTK 37.6M
- SXTC 34.4M
- IPO Year
- STTK 2020
- SXTC 2019
- Fundamental
- Price
- STTK $1.00
- SXTC $1.74
- Analyst Decision
- STTK Hold
- SXTC
- Analyst Count
- STTK 4
- SXTC 0
- Target Price
- STTK $3.00
- SXTC N/A
- AVG Volume (30 Days)
- STTK 112.0K
- SXTC 710.8K
- Earning Date
- STTK 07-31-2025
- SXTC 01-01-0001
- Dividend Yield
- STTK N/A
- SXTC N/A
- EPS Growth
- STTK N/A
- SXTC N/A
- EPS
- STTK N/A
- SXTC 20.77
- Revenue
- STTK $4,606,000.00
- SXTC $1,818,404.00
- Revenue This Year
- STTK N/A
- SXTC N/A
- Revenue Next Year
- STTK N/A
- SXTC N/A
- P/E Ratio
- STTK N/A
- SXTC $0.08
- Revenue Growth
- STTK 69.65
- SXTC 6.78
- 52 Week Low
- STTK $0.69
- SXTC $0.95
- 52 Week High
- STTK $4.99
- SXTC $11.92
- Technical
- Relative Strength Index (RSI)
- STTK 47.54
- SXTC 48.66
- Support Level
- STTK $0.91
- SXTC $1.65
- Resistance Level
- STTK $1.14
- SXTC $1.95
- Average True Range (ATR)
- STTK 0.08
- SXTC 0.25
- MACD
- STTK -0.01
- SXTC 0.00
- Stochastic Oscillator
- STTK 28.35
- SXTC 42.20
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.